What is a Bispecific Antibody?
Bispecific antibodies (BsAbs) are engineered antibodies with the unique ability of binding simultaneously to two targets (antigens or epitopes), showing great efficacy, specificity, and safety profiles. The applicability of BsAbs being developed covers intercellular bridging, proximity effects, dual target inhibition, and cell targeting dependent on two antigen types. They have become of great interest in cancer therapies; nonetheless, in recent years, more BsAbs have also been launched in other therapeutic areas.
Antibodies are composed of the Fragment crystallizable domain (Fc), which is a constant region that interacts with cell receptors and the complement, and the Fragment antigen-binding domain (Fab) that contains a Variable Heavy chain and a Variable Light chain; this region is the one that recognizes the target.
The BsAbs are engineered to have two different arms in the Fab region, with their own different Variable Light and Heavy chains, each one capable of recognizing a specific target and therefore enabling them to bind to two antigens simultaneously. When engineering BsAbs, a major consideration is to guarantee the proper assembly of the two different heavy and light chains of the Fab region. Furthermore, BsAbs modifications to the Fc promote and enhance their stability, modify immune functions, and increase their half-life.
In the development of BsAbs, it is essential to select the optimal candidate. Such selection is based on physicochemical properties, format, specificity, pharmacokinetics (PK), and intended therapeutic effects.
Which Parameters are Usually Considered in BsAbs Development?
To ensure safety, quality, and efficacy, analytical programs must evaluate several critical quality attributes (CQAs) across four main categories:
-
Safety: Endotoxins, Mycoplasma, Immunogenicity (ADA, NAb), pathogen presence.
-
Quality: Glycosylation, Aggregation, Host-Cell Proteins (HCP), Host-Cell DNA (HCDNA).
-
Identity and Purity: Size, Amino-acid sequence, Glycan analysis (ELISA, LC-MS, SEC-HPLC, SDS-PAGE).
-
Potency: Target Binding (ELISA, SPR), Cellular response and Cytotoxicity (Cell-based Assays, ADCC).
Preclinical and Clinical Considerations in BsAbs Development
Pharmacokinetics (PK)
BsAbs present unique pharmacokinetic challenges that impact the assessment of PK profiles, dose schemes, half-life, and clearance. Because BsAbs have low stability in the gastrointestinal tract and decreased permeability in the gut wall, they are not appropriate oral candidates. Instead, BsAbs can be administered via intravenous (IV), intraperitoneal (IP), or subcutaneous (SC) injection.
Their molecular size and other physicochemical properties directly affect their distribution and tissue permeation. The BsAbs Fc region is responsible for maintaining and enhancing systemic presence, thereby reducing the need for frequent dosing.
Because the PK profile and linearity may be different than conventional monoclonal antibodies (mAbs), it is critical for PK bioanalytical studies to establish exactly what analyte or analytes need to be measured, whether that means total antibody, individual active arms, or bound complexes.
Pharmacodynamics (PD)
As part of the safety evaluation, specific biomarkers and cytokines can be measured. This is a vital step during dose-escalation phases, as increased doses may cause cytokine release syndrome (CRS).
Immunogenicity Risk
Evaluating anti-drug antibodies (ADA) is significantly more challenging when compared with standard ADA assays for conventional mAbs. The traditional multi-tiered approach must undergo an additional characterization step during the confirmatory stage to map responses against each individual functional domain of the bispecific molecule.
Regulatory Compliance Framework
Developing robust bioanalytical methods requires strict adherence to international regulatory frameworks. Key guidance includes:
-
ICH M10: Bioanalytical Method Validation Guideline.
-
EMA Guidelines: Guideline on the Clinical Investigation of Pharmacokinetics of Therapeutic Proteins, including specific emphasis on detailed characterization of product-related impurities (such as Section 7.4 of the 2017 guideline).
-
FDA Guidance: Bispecific Antibody Development Programs Guidance for Industry (2021) and the 2019 guidance frameworks (including Section IV.A.3).
BsAbs PK and Immunogenicity Challenges: Kymos Experience
It is true that BsAbs present additional analytical challenges compared to conventional monoclonal antibodies due to their structural complexity and dual-target binding properties.
Based on our experience, particular attention is required during assay development. It is important to thoroughly evaluate potential target interferences. Additionally, it is crucial to select the most suitable assay format, carefully characterize critical reagents, and ensure adequate assay performance in the desired biological matrix.
Through our BsAb projects, we have gained valuable experience in dealing with the common challenges associated with these molecules. With comprehensive and detail-oriented development and optimization of analytical methods, we believe that robust and reliable PK and ADA assays can be established. This paves the way for the successful development of analytical methods for additional BsAbs that can be applied in both preclinical and clinical programs.
How Can Kymos Group Assist in the Development of BsAbs?
Kymos Group provides a comprehensive suite of analytical capabilities to support both the bioanalytical and CMC requirements of complex biologics:
-
CMC and Physicochemical Properties: Antibody characterization, molecular size, sequence determination, and microbiological testing.
-
Functional and Potency Testing: Target binding and protein interactions via ELISA or SPR, alongside cytotoxicity and cell-based potency assays.
-
Preclinical and Clinical Bioanalysis: Pharmacokinetic level evaluation by Ligand Binding Assays (LBA).
-
PD and Biomarkers: Multiplexing capability for tracking different cytokines, factors, and interleukins.
-
Advanced Immunogenicity: Assays for total binding ADA, detailed domain characterization, and Neutralizing Antibody (NAb) detection.
One-Stop-Shop Solutions for Bispecific Antibodies
We provide our clients with full-pack assistance on their projects by merging our specialized preclinical and clinical CRO capabilities, covering PK, immunogenicity, biomarkers, and thorough structural characterization under one regulatory umbrella.
Conclusion
The development of therapeutic antibodies is overcoming the limitations of conventional monoclonal antibodies (mAbs) through the engineering of BsAbs. Their dual-targeting mechanism of action enables them to act effectively over complex disease pathways. However, this unique characteristic, alongside their complex structural architecture, underscores the absolute necessity of performing a thorough, reliable investigation into both efficacy and safety attributes. As new engineering strategies emerge continuously to target more clinical conditions, this evolving field requires robust analytical support and advanced technology at every phase of development.
References
-
Tetsuya Wakabayashi, Taichi Kuramochi (2025) Discovery and development of bispecific antibodies. Protein Expr Purif. 2025 Dec:236:106787. doi: 10.1016/j.pep.2025.106787. Epub 2025 Aug 5.
-
Ding Y, Andrien B, Sarkar M and Aimone M (2024). Process Development, Manufacturing, and Clinical Support for Bispecific Antibodies: Chemistry, Manufacturing, and Controls Considerations. BioProcess International 22(11–12).
-
Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2021). Bispecific Antibody Development Programs Guidance for Industry. U.S. Center for Biologics Evaluation and Research (CBER) Pharmaceutical Quality/CMC.
-
Choi et al. (2024). Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies. Biomol Ther (Seoul) 2024 Oct 25;32(6):708–722. doi: 10.4062/biomolther.2024.146.
